Artiva Biotherapeutics (NASDAQ:ARTV) Receives “Buy” Rating from Needham & Company LLC

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports. They currently have a $23.00 price objective on the stock. Needham & Company LLC’s price target indicates a potential upside of 488.24% from the stock’s previous close.

Separately, HC Wainwright assumed coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 target price for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $21.00.

Artiva Biotherapeutics Stock Down 8.4 %

Shares of NASDAQ:ARTV opened at $3.91 on Tuesday. The firm’s 50-day simple moving average is $4.97 and its 200-day simple moving average is $9.43. Artiva Biotherapeutics has a fifty-two week low of $3.37 and a fifty-two week high of $17.31.

Institutional Trading of Artiva Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. RA Capital Management L.P. acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $152,234,000. Franklin Resources Inc. purchased a new position in Artiva Biotherapeutics during the third quarter worth $7,435,000. Geode Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics in the third quarter worth $4,774,000. Samsara BioCapital LLC acquired a new position in shares of Artiva Biotherapeutics in the third quarter worth $4,506,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Artiva Biotherapeutics in the third quarter valued at $2,912,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.